Target Ovarian Cancer is delighted to announce that Emma Kane has been appointed Chair of our Board of Trustees.
Emma was first appointed as a trustee for Target Ovarian Cancer in March 2015 and is the Chief Executive of Redleaf Communications, Chairman of the Barbican Centre Trust, and a trustee of Nightingale Hammerson. Emma's stepchildren's mother, Heather Ash, died from ovarian cancer at the age of 52 in 2007.
Joanna Barker, the previous Chair, founded Target Ovarian Cancer in 2008 after her mother and sister both died from ovarian cancer within three weeks of each other. Target Ovarian Cancer adheres to the highest standards of governance, which includes rotation of trustees and Board renewal. Having served three terms as Chair, Joanna now steps down from the Board for a minimum of a year before returning.
For the same reason, we also bid farewell to trustees Lisa Attenborough and Sonya Branch, who have served two three-year terms as trustees and rotate off the Board.
Sadly trustee Charlie Parker has also resigned, as he has been offered a new post within the Four Seasons hotel group in Hawaii.
We are delighted to announce in turn that two new trustees have been appointed to the Board – Alexandra Cran-McGreehin and Andrew Harrison.
Emma said: “I’m delighted to have become Chair of Target Ovarian Cancer at such an exciting time. We have high ambitions and a strong business plan. We know we are at a pivotal moment for ovarian cancer – it really is time for the ovarian cancer community to TAKE OVAR.
“We are so sad to say goodbye to Lisa, Sonya and Charlie, and I thank them for their leadership and counsel over the past years. We will continue to work with them, and I know we will continue to benefit from their support in different forms. I also know that we maintain our strong leadership with the appointment of Alexandra and Andrew, and I extend them a warm welcome.”
Joanna said: “Good governance is essential for any successful organisation, and it is best practice for trustees to rotate off the Board after a standard period. I’m proud of how much Target Ovarian Cancer and the ovarian cancer community have achieved in the past 10 years. I’m pleased to be handing over to such a talented team as we enter this period of opportunity, and look forward to returning to great progress.”